Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 3Phase NA 2Phase 1/2 2

Status

Unknown 3Not yet recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 3Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Aclarubicin × Clear all
NCT07535762 2026-04-17

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma

Shanghai Jiao Tong University School of Medicine

Phase 2 Not yet recruiting
36 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT04254640 2020-12-17

Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML

Sun Yat-sen University

Phase 2 Unknown
34 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03181815 2019-08-20

Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia

Sun Yat-sen University

Phase 2 Unknown
48 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03045627 2017-02-07

Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients

Shandong University

Phase 2 Unknown
120 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡